Posted by Michael Wonder on 03 Aug 2022
Pralsetinib for treating advanced RET fusion positive non-small-cell lung cancer
3 August 2022 - NICE has published evidence-based recommendations on the use of pralsetinib (Gavreto) for the treatment of adults with RET fusion positive advanced non-small-cell lung cancer.
The use of pralsetinib is not recommended for the treatment of adults with advanced RET fusion positive non-small-cell lung cancer who are RET inhibitor naïve.
